1. Immunology/Inflammation
  2. PD-1/PD-L1
  3. PD-1/PD-L1-IN 3

PD-1/PD-L1-IN 3 

Cat. No.: HY-103048
Handling Instructions

PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.

For research use only. We do not sell to patients.

PD-1/PD-L1-IN 3 Chemical Structure

PD-1/PD-L1-IN 3 Chemical Structure

CAS No. : 1629654-95-0

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of PD-1/PD-L1-IN 3:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases[1].

IC50 & Target

IC50: 5.60 nM (PD-1/PD-L1); 7.04 nM (CD80/PD-L1)[1]

In Vitro

PD-1/PD-L1-IN 3 (0.1 nM-10 μM) inhibits the binding of PD-1 and CD80 to PD-L1, with IC50s of 5.60 nM and 7.04 nM[1].
PD-1/PD-L1-IN 3 blocks the binding of recombinant PD-L1-Ig to Jurkat-PD-1 cells, and also block binding of recombinant PD-1-Ig to either L2987 or LK35.2-hPD-L1, with IC50s of 26 nM, 12 nM, and 3.5 nM, respectively[1].
PD-1/PD-L1-IN 3 (0.001-100 μM) promotes IFN secretion by CMV-specific T cells in a dose-dependent manner, with an EC50 of 400 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1852.17

Formula

C₈₉H₁₂₆N₂₄O₁₈S

CAS No.

1629654-95-0

Sequence Shortening

Maa-FANPHL-Sar-WSW-Nle-Nle-RCG (Disulfide bridge: Maa1-Cys15)

SMILES

O=C(N([[email protected]](C(N([[email protected]](C(N[[email protected]](C(N[[email protected]](CSCC(N[[email protected]](C(N([[email protected]](C(N[[email protected]](C(N1CCC[[email protected]]1(C(N[[email protected]]([H])(C(N[[email protected]](C(N(CC(N[[email protected]](C(N[[email protected]](C2=O)CO)=O)CC3=CNC4=CC=CC=C34)=O)C)=O)CC(C)C)=O)CC5=CN=CN5)=O)[H])=O)CC(N)=O)=O)C)C)=O)CC6=CC=CC=C6)=O)([H])C(NCC(N)=O)=O)=O)CCCNC(N)=N)=O)CCCC)C)=O)CCCC)C)[[email protected]](N2)([H])CC7=CNC8=CC=CC=C78

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

PD-1/PD-L1-IN 3PD-1/PD-L1PD-1/Programmed death-ligand 1cancerinfectiousinteractionbindingregionssensitiveresistantInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PD-1/PD-L1-IN 3
Cat. No.:
HY-103048
Quantity:
MCE Japan Authorized Agent: